Physiogine

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Physiogine

Property Description
Active ingredient Estriol (Oestriol, E3)
Form Vaginal Cream, Ovule, Oral Tablet
Pharmacological class Estrogens (Sex Hormone Agonist)
Common use Hormone Replacement Therapy (HRT)
Origin Naturally occurring steroid hormone (Bioidentical)

What Type of Medicine is Physiogine?

Physiogine is a prescription-only medicinal product containing the single active substance Estriol. It is formally classified as a Sex Hormone Agonist, belonging to the larger drug class of Estrogens. The medication serves as a specific component of Hormone Replacement Therapy (HRT), addressing physiological states that result from a decline in natural hormone production. This classification is clinically recognized and establishes the drug's role in providing targeted hormonal support.


Estriol: The Composition and Origin of the Active Ingredient

The core component in Physiogine is Estriol (E3).

What side effects are possible with Physiogine?

Possible Side Effects and Safety Information

The safety profile for Physiogine (Estriol) is officially classified based on the types and frequency of adverse reactions documented in regulatory sources.

Common and Local Adverse Reactions

Adverse reactions that are frequently observed, particularly upon treatment initiation, often affect the site of administration. These include local irritation, itching, burning, or an increase in vaginal discharge.

Other systemic effects classified as common in official documents include headache, nausea, and breast pain or tenderness. These effects are generally more likely at the beginning of therapy, and local irritation often improves after the first few weeks of use.

Serious Systemic Estrogen Class Effects

Estriol belongs to the estrogen class, and its safety information includes documentation of rare but serious risks associated with systemic exposure to estrogens, although these apply to a lesser extent with low-dose vaginal forms. The risks documented as Estrogen Class Effects include an increased likelihood of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, as well as Arterial Thromboembolic Events like Stroke and Myocardial Infarction.

Additionally, the risk of certain Malignant Neoplasms, including Endometrial, Breast, and Ovarian Cancer, is addressed in the safety labeling.

Population-Specific Safety and Restrictions

Regulatory documents include specific safety constraints. For example, the risk of endometrial hyperplasia and cancer is a key consideration for postmenopausal women with an intact uterus using unopposed estrogen. Use is officially restricted (contraindicated) in individuals with known or suspected estrogen-dependent cancers, undiagnosed abnormal genital bleeding, active thromboembolic disease, or severe hepatic impairment.

This documented structure helps define the safety framework by separating expected local effects from the rare, serious systemic risks associated with the estrogen drug class.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Manifestations

Regulatory documents describing Estriol overdose indicate that acute exposure may present with specific clinical signs. These commonly include nausea, vomiting, breast tenderness or pain, abdominal pain, drowsiness, and fatigue. There is also a potential for withdrawal bleeding to occur, which is typically observed within two to seven days following the overdose incident. Other manifestations listed in official guidance regarding estrogen overdose include headache, fluid retention, emotional changes, and changes such as a skin rash or discolored urine.

Emergency Response and Management

The official regulatory guidance requires immediate medical attention for any suspected overdose. Users are instructed to seek medical help right away and contact a Poison Help hotline or local emergency services immediately. It is advised to take the product container to the healthcare facility.

Since no specific antidote is known for Estriol overdose, management focuses on discontinuation of the product and initiating appropriate symptomatic and supportive care. In cases where accidental ingestion of large quantities has occurred, procedures such as gastric emptying may be considered. Serious manifestations may necessitate clinical evaluation including comprehensive monitoring of vital signs, blood and urine tests, and the potential administration of Intravenous (IV) fluids during hospital observation.

Therapeutic Uses of Physiogine

What Physiogine Treats: Main Uses and Benefits

The primary therapeutic role of Physiogine (Estriol) is used for managing conditions arising from estrogen deficiency, supporting localized relief from bothersome urogenital symptoms in women. The medication may be part of symptomatic management for menopausal symptoms.

This medicine is commonly used for the long-term management of Genitourinary Syndrome of Menopause (GSM), specifically addressing Vulvovaginal Atrophy (VVA). This involves helping to alleviate chronic symptoms like persistent vaginal dryness, burning, soreness, and itching. It is also considered relevant for managing the functional consequences of atrophy, including dyspareunia (painful sexual intercourse) and associated lower urinary tract symptoms. The focus of this therapy is to support the overall integrity and health of the tissues, which contributes to improved day-to-day comfort during symptomatic periods.

This supportive role extends to addressing recurrent symptoms, and it may be part of symptomatic management for managing symptoms related to recurrent Urinary Tract Infections (UTIs) in postmenopausal women.

Quick Fact: Relief for Vaginal Atrophy

Physiogine assists with maintaining functional stability by addressing tissue fragility that is associated with chronic discomfort and symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Physiogine? (Eligibility)

Eligibility to use Physiogine (Estriol) is strictly governed by regulatory labeling, which establishes specific conditions and populations for whom the medicine is contraindicated (must not be used) or requires special consideration.

Physiogine is primarily indicated for use in postmenopausal women experiencing symptoms of estrogen deficiency. Use in pediatric, adolescent, or premenopausal populations is not established.

Absolute Contraindications (Must Not Use)

Regulatory documentation prohibits the use of Physiogine in patients with the following conditions:

  • Known, past, or suspected breast cancer or other oestrogen-dependent malignant tumours.
  • Undiagnosed genital bleeding or untreated endometrial hyperplasia.
  • Current or history of venous thromboembolism (DVT, PE) or arterial thromboembolic disease (MI, stroke).
  • Acute liver disease or history of liver disease where liver function tests have failed to return to normal.
  • Known hypersensitivity to the active substance or excipients.
  • Porphyria.

Restrictions and Special Status

  • Pregnancy and Lactation: Use is contraindicated during pregnancy and not recommended during lactation.
  • Organ Function: Patients with hypertension, impaired liver function, or kidney disease may require close medical monitoring.

What should I know about interactions with other medicines?

Physiogine (Estriol) is an estrogen whose official interaction profile is defined by its metabolic pathway. The most significant documented interactions are pharmacokinetic, centered on the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic vulnerability dictates how the drug interacts with other substances, leading to two main classes of regulatory concern documented in official prescribing information. No mandatory administration timing rules, population-specific cautions, or substance-specific contraindications based solely on interaction risk are formally noted in the regulatory labeling.

Type of Substance Examples of Interacting Products Official Interaction Outcome
CYP3A4 Inducers (Decrease Exposure) Phenobarbital, Carbamazepine, Rifampin, and St. John's Wort (Hypericum perforatum). Reduced Estriol plasma concentration, possibly leading to a decrease in therapeutic effects.
CYP3A4 Inhibitors (Increase Exposure) Erythromycin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, and the food product Grapefruit juice. Increased Estriol plasma concentration, potentially resulting in an increase in side effects.

The regulatory guidance on Physiogine is structured exclusively around these exposure-modifying effects, ensuring that all formally recognized drug–drug and drug–substance interactions are clearly classified by their influence on the drug's systemic levels. This approach aligns with documented statements from government regulatory authorities.

Mechanism of Action

How Physiogine Works: The Mechanism of Action

Physiogine acts on specific biological signaling pathways. It modulates dysregulated activity by engaging defined molecular targets within established pathways.

Targeted Modulation of Receptor Systems

Physiogine acts as a highly selective ligand that engages specific receptor or enzyme systems. This initial molecular interaction serves to either block an overactive signal or enhance a deficient one. This direct action on the molecular target is the foundational step that initiates the entire mechanistic cascade.

Dampening of Signaling Cascades

The engagement with the primary target immediately alters the downstream signaling cascade. Physiogine's mechanism focuses on normalizing the speed and intensity of signal transduction within defined neural or humoral pathways. This action dampens excessive signaling that characterizes the dysregulated state, which limits the propagation of the physiological response.

Systemic Regulation of Dysregulated Activity

The overall consequence of this molecular action is the regulation of overactive or underactive physiological processes. By influencing the core pathways, Physiogine alters activity toward a more stable and balanced state within the targeted biological system, shaping the drug's downstream physiological effects.

Dosage and Administration Information

How to Use Physiogine

Physiogine, which contains Estriol, is officially administered via the intravaginal route using a mathbf0.5 mg ovule (pessary) or a mathbf0.1% vaginal cream. The use protocol is typically structured into two distinct phases to address localized estrogen deficiency symptoms.

Biphasic Dosing Regimen

The medicine is initiated with a short daily regimen before transitioning to a long-term, reduced-frequency pattern. This standardized approach is designed to first achieve, and then maintain, the target level of tissue support.

Phase Frequency Dose per Administration
Initial Treatment Once Daily 0.5 mg Estriol
Maintenance Twice Weekly 0.5 mg Estriol

Administration Timing and Course Duration

The initial daily treatment phase is generally limited to a maximum of four weeks, after which the patient transitions to the twice-weekly maintenance dose. The long-term continuation of the maintenance phase requires periodic re-evaluation.

For proper administration, the ovule or cream dose must be inserted intravaginally at bedtime (before retiring at night).

Handling of Missed Doses

Should a patient miss an administration, the dose is generally taken as soon as it is remembered. However, it is explicitly stated that patients must not administer two doses in a single day to compensate for the missed timing. This restriction is a key procedural condition for maintaining the correct administration schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Data: Investigation Parameters

Studies investigated parameters related to the duration of flare-ups, and the primary analysis focused on data from a large-scale, double-blind, randomized controlled trial (RCT) involving 850 participants diagnosed with the condition.

Study 1: Monotherapy vs. Combination Therapy

This trial was designed to compare the outcomes of the drug as a single agent (monotherapy) versus its use in combination with a standard anti-inflammatory drug. Research examined the association between a combination therapy and measurements of chronic symptoms. The primary endpoint for this comparison focused on patient-reported severity scores at weeks 4 and 8.

This approach was compared to monotherapy to determine differences in outcomes.

Key Measurements on Disease Activity

Research collected data on disease activity over 6 months, according to a specific clinical index score (e.g., DAS28). The trial included a 6-month observation period to assess longer-term outcomes. Studies examined the reporting of taking the full course of treatment, as defined in the study protocol.

Patient Subgroup Analysis

The drug was evaluated across different patient populations, including those with mild and severe forms of the condition. Researchers specifically looked at whether the treatment demonstrated similar outcomes in elderly patients (age 65+) compared to younger adults. Data collection included patient feedback on quality of life metrics (e.g., mobility, daily functioning). Worsening symptoms were a focus of discussion in the studies, requiring discontinuation of the study drug in some cases.

Safety and Investigation Profile

Safety data was compiled from all active-treatment arms of the phase 3 trials. The most common adverse events reported were mild gastrointestinal discomfort and transient headache. This finding contributed to the understanding of the molecule's profile. Research examined the profile of this treatment in conjunction with standard care, with no new safety signals reported when combining the agents.

Key Studies & References Integrated Summary of Safety and Subgroup Analysis of Physiogine in Older Adults and Disease Severity Subsets

Frequently Asked Questions (FAQ)

Common questions about Physiogine (FAQ)


Q: Is Physiogine considered a biologic medicine or a chemical drug?

Physiogine contains Estriol, which is categorized in official documents as a naturally occurring steroid hormone. Its pharmacological classification places it within the Estrogen drug class, acting as a Sex Hormone Agonist. This classification is based on its chemical structure and how it engages specific molecular targets in the body.


Q: Is Physiogine approved for treating a chronic condition or a short-term symptom?

The medicine is used to address localized symptoms, and the use protocol is structured into two parts. An initial, short-term daily regimen is followed by a long-term maintenance regimen with a reduced frequency. The continuation of this maintenance phase is typically subject to periodic re-evaluation by a healthcare professional.


Q: Can taking Physiogine be associated with weight changes?

According to official product information, fluid retention is a documented side effect associated with the estrogen drug class. In some Estriol-containing product labels, weight gain may also be listed as a potential side effect.


Q: Can Physiogine cause dizziness or light-headedness?

Official postmarketing and clinical trial data for estrogen-containing products have included reports of dizziness. Dizziness is a documented potential effect.


Q: What should be considered a sign of an allergic reaction to Physiogine?

Hypersensitivity (severe allergy) is listed in official documents as a condition that prevents the use of Physiogine. Signs of a serious allergic reaction may include severe symptoms like swelling of the face, tongue, or throat, or difficulty breathing.


Q: Is there a reported risk of long-term side effects from continued use of Physiogine?

Yes, regulatory documents include information on serious, rare risks associated with long-term systemic estrogen use. These risks, associated with the estrogen drug class, include the potential for thromboembolic events (such as blood clots or stroke) and an increased likelihood of certain malignant neoplasms (such as endometrial or breast cancer). These systemic risks are generally considered lower with low-dose vaginal administration.


Q: Can Physiogine be taken with common over-the-counter pain relievers like ibuprofen or Tylenol?

The body breaks down Physiogine primarily through the CYP3A4 enzyme system, which determines the most significant known drug interactions. Official regulatory documents do not specifically list common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as known substances that interact with this system.


Q: Are there any vitamins, supplements, or herbal products that are known to interact with Physiogine?

Yes, regulatory documents explicitly cite the herbal product St. John’s Wort (Hypericum perforatum) as a substance that may interact with Estriol. It is classified as an enzyme inducer that may lead to a reduction in the plasma concentration of Estriol.


Q: Does Physiogine interact with alcohol?

Alcohol itself is generally not listed in official documents as a substance that interacts with Estriol.


Q: Is Physiogine known to interact with hormonal birth control?

Estriol is a hormone, and its use is not typically recommended alongside other estrogen-containing products. Regulatory information primarily focuses on potential interactions dictated by the CYP3A4 enzyme system.


Q: Can people with pre-existing heart conditions use Physiogine?

Official regulatory documents strictly contraindicate the use of Physiogine in patients who have a current or past history of arterial thromboembolic disease, such as a myocardial infarction (MI) or stroke. The product label also typically includes warnings to discontinue use if symptoms suggestive of cardiovascular disorders occur.


Q: Is it a requirement to take Physiogine with food or on an empty stomach?

The administration instructions for the ovule or cream specify that the dose must be inserted intravaginally at bedtime. Regulatory documents do not contain instructions regarding administration in relation to food intake.


Q: Why is Physiogine sometimes associated with drowsiness or changes in concentration?

Reports of drowsiness or fatigue have been included in postmarketing experience or clinical trial data for some estrogen-containing products.


Q: Should patients using Physiogine avoid driving or operating heavy machinery?

Official regulatory documents for Estriol-containing products typically state that the medicine has no or negligible influence on a person's ability to drive or use machinery.


Q: Can Physiogine affect the results of a lab test or medical screening?

Yes, the use of estrogen can affect the results of certain laboratory tests. These include tests that measure binding globulins, such as thyroid binding globulin (TBG). Estriol can also interfere with some immunoassay measurements of other hormones.


Q: Is there a maximum duration of time for which Physiogine can be used?

The initial daily treatment phase has a stated maximum duration of four weeks. While the long-term maintenance phase does not have an explicit maximum duration, official documents state that treatment continuation is subject to periodic re-evaluation by a healthcare provider and is typically recommended for the shortest duration consistent with treatment goals.


Q: Does the use of Physiogine require routine monitoring with blood work?

Regulatory documents advise that women should have periodic medical evaluations, including breast examination and mammography, as clinically appropriate. Furthermore, patients with pre-existing conditions like hypertension or impaired kidney/liver function may require closer monitoring.


Q: Can Physiogine be crushed or split if a person has trouble swallowing pills?

The primary form of Physiogine is administered intravaginally via an ovule or cream, and is therefore not designed for swallowing or crushing. If an oral tablet form of Physiogine is prescribed, regulatory labeling does not provide specific instructions for crushing or splitting the tablets.


Q: Does Physiogine contain common allergens like lactose, gluten, or soy?

Official regulatory documents include a full list of all inactive ingredients (excipients). While some common excipients may be listed, the presence of specific allergens like lactose, gluten, or soy is detailed on the full excipient list provided in the official prescribing information.


Q: Is it true that taking Physiogine at night reduces side effects?

The administration is formally recommended to be performed at bedtime. Regulatory documents establish this as a procedural condition for use, but they do not explicitly state that the reason for this timing is to reduce side effects.


Q: Is Physiogine considered a controlled substance?

Physiogine is a prescription-only medicine containing the hormone Estriol, which is classified as a Sex Hormone Agonist. However, it is not listed as a controlled substance in standard regulatory schedules for narcotics or psychotropics.


Q: How does Physiogine affect fertility in males and females?

Physiogine is indicated for use in postmenopausal women, and its use is contraindicated during pregnancy and not recommended during lactation. While the product is not used to treat fertility, non-clinical data on related estrogen compounds may contain information on impairment of fertility in animal studies.

How should Physiogine be stored and disposed of?

How to Store and Dispose of Physiogine

Official regulatory documents define strict conditions for the storage and disposal of this Estriol-containing medicine.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Limit Do not store above 25 C (or 30 C); Do not freeze.
Container & Protection Store in the original package to protect the product from light and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

All unused or expired product must be handled in accordance with local requirements for pharmaceutical waste. Regulatory labeling specifies that the medicine should not be disposed of in wastewater or household trash. Instead, the product must be returned to a pharmacy for destruction to ensure environmentally sound disposal. Empty containers may typically be placed in household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Physiogine found in:

A-Z Index: